Clinical trials: Metabolism and Nutrition Disorder
Alzheimer's Disease, Parkinson's Disease
Evaluation of a Diet in Patients With Senile Dementia
The most common symptoms associated to senile dementia disease are confusion about schedules, hyperactivity... In this sense, these patients have frequently poor nutrition, resulting in malnutrition problems or malnutrition high…
- Conditions
- Alzheimer's Disease, Parkinson's Disease, Senile Dementia
- Trial name
- SUPRESSI (NCT01192529)
- Testing
- Supressi. T-Diet plus Range, High Protein. T-Diet plus Range
- Where
- 3 sites in Spain
- Volunteers
- 184 people
- Sponsor
- Vegenat, S.A.
Obesity
Study to Evaluate ARD-101 in Adults With Obesity
The purpose of this study is to evaluate safety and efficacy of twice-daily ARD-101 in obese subjects with a body mass index (BMI) of 30-45 kg/m2.
- Trial name
- NCT05121441
- Testing
- ARD-101
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Aardvark Therapeutics, Inc.
Overweight, Obesity
RCT to Compare Orlistat and Polyglucosamine for the Management of Overweight and Obesity
This trial compares two treatment methods: 1. Orlistat 60 mg to be taken three times daily one capsule; indicated for weight loss in overweight adults.
- Trial name
- NCT02529631
- Testing
- orlistat 60 mg, polyglucosamine
- Where
- 2 sites in Germany, Italy
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Certmedica International GmbH
Overweight, Obesity
Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
This study will look at the change in body weight from the start to the end of the study. Researchers will compare the weight loss in people taking semaglutide (a new medicine) to people taking "dummy" medicine.
- Trial name
- STEP 5 (NCT03693430)
- Testing
- Semaglutide
- Where
- 41 sites in United States, Canada and 3 more
- Volunteers
- 304 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin
The purpose of this study is to characterize the Influence of HDM1005 on gastric emptying and drug-drug interaction of HDM1005 and metformin, atorvastatin, warfarin, and digoxin in overweight/obese adult subjects.
- Trial name
- NCT07502001
- Testing
- Acetaminophen, Metformin, Warfarin
- Where
- China
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
PKU, Phenylketonurias
Market Research - Acceptability Trial for a New PKU Amino Acid Based Protein Substitute
The aim of this study is to demonstrate that a new protein substitute is acceptable and well tolerated in children with PKU.
- Conditions
- PKU, Phenylketonurias, Inborn Errors of Metabolism, Metabolic Disease
- Trial name
- NCT04309331
- Testing
- Motion
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Dr. Schär AG / SPA
Obesity
Phase 2a Obesity Study of Oral Doses of Oleoyl-Estrone (MP-101)
The purpose of this study is to evaluate the safety, preliminary efficacy, and pharmacokinetics of two 14-day cycles of escalating oral doses of MP 101 in 100 obese adult subjects.
- Trial name
- NCT00449202
- Testing
- oleoyl-estrone (MP 101)
- Where
- 3 sites in United States, Switzerland
- Volunteers
- 100 people
- Sponsor
- Manhattan Pharmaceuticals
Overweight, Obesity
A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities
The main purpose of this study is to learn about the safety and tolerability of LY3502970 when given to Chinese participants with obesity or overweight with weight-related comorbidities.
- Trial name
- NCT06023095
- Testing
- LY3502970
- Where
- 3 sites in China
- Volunteers
- 24 people
- Sponsor
- Eli Lilly and Company
Overweight or Obesity
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US
This study will test olatorepatide (study drug) to determine how safe and effective this drug is and how easily your body can accept this drug without causing side effects, as well as how the drug is processed in the body by…
- Trial name
- NCT07431086
- Testing
- Olatorepatide
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Regeneron Pharmaceuticals
Obesity
Study To Evaluate The Effect Of Two Steady State Doses of PF 06882961 On Rosuvastatin And Midazolam Pharmacokinetics In Otherwise Healthy Adult Participants With Obesity
A Phase 1 Study To Evaluate The Effect Of Two Steady State Doses of PF 06882961 On Rosuvastatin And Midazolam Pharmacokinetics In Otherwise Healthy Adult Participants With Obesity
- Trial name
- NCT04621227
- Testing
- PF-06882961, Rosuvastatin, Midazolam
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Pfizer
Overweight, Obesity
Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity
This study will look at participants' body weight from the start to the end of the study. The study will last for about 1½ years.
- Trial name
- STEP 8 (NCT04074161)
- Testing
- Semaglutide, Liraglutide
- Where
- 19 sites in United States
- Volunteers
- 338 people
- Sponsor
- Novo Nordisk A/S
Overweight and Obesity
A Study to Investigate the Safety and Efficacy of TE-8105 in Overweight or Obesity Participants
This is a Phase 2b, randomized, double-blind, placebo-controlled, multiple ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of TE-8105 in adults with overweight or obesity…
- Trial name
- NCT07857473
- Testing
- TE-8105 MAD Cohort 1, TE-8105 MAD Cohort 2, TE-8105 MAD Cohort 3
- Where
- 2 sites in Australia
- Volunteers
- 204 people
- Sponsor
- Immunwork, Inc.
Blood Sugar; High, Overweight and Obesity
Glucagon Like Peptide 1 (GLP-1) Booster™ RCT Study
BACKGROUND GLP1 booster (GB) was designed to stimulate the endogenous production of GLP1, which in turn releases insulin, controls blood glucose level, suppresses appetite and thus helps people lose weight.
- Conditions
- Blood Sugar; High, Overweight and Obesity, Fat Loss, GLP-1
- Trial name
- RCT (NCT07141472)
- Testing
- GB
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Lawry Han
Overweight, Obesity
A Study to Evaluate the Effects of a Dietary Supplement on Weight Management and Appetite Control
This is a randomized, double-blind, placebo-controlled, decentralized clinical trial evaluating the effects of MN Nutra GeLiPthin-1™, a multi-ingredient dietary supplement, on body weight, BMI, waist circumference, appetite…
- Conditions
- Overweight, Obesity, Weight Management, Appetite Control
- Trial name
- NCT07895563
- Testing
- MN Nutra GeLiPthin-1™ Dietary Supplement
- Where
- United States
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- MNnutra
Obesity, Overactive Bladder
Trospium Chloride XR in Obese Female Patients With Overactive Bladder
This study evaluated the effectiveness of trospium chloride extended release (XR) in obese female patients with overactive bladder (OAB). Patients received either placebo and trospium chloride XR or placebo only.
- Conditions
- Obesity, Overactive Bladder, Incontinence
- Trial name
- NCT00932022
- Testing
- Trospium Chloride, Extended Release (XR)
- Where
- United States
- Volunteers
- 127 people
- Sponsor
- Allergan
Obesity, Overweight and Obesity
Improving Quality of Life in Men and Women With Overweight or Obesity
The purpose of this study is to evaluate the effect of the Noom Healthy Weight Program, a digital behavior change weight loss intervention, on quality of life as measured both by self-report and objective measures, compared to a…
- Conditions
- Obesity, Overweight and Obesity, Quality of Life, Health Behavior
- Trial name
- NCT04871295
- Testing
- Noom Healthy Weight
- Where
- United States
- Volunteers
- 370 people, healthy volunteers welcome
- Sponsor
- Noom Inc.
Obesity, Overweight
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
The main purpose of this study is to see how orforglipron, compared with placebo, helps improve glycemic control in participants with obesity or with overweight and type 2 diabetes.
- Conditions
- Obesity, Overweight, Type 2 Diabetes
- Trial name
- NCT06972472
- Testing
- Orforglipron
- Where
- 80 sites in United States, Argentina and 5 more
- Volunteers
- 600 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
Placebo-Controlled Clinical Nutrition Study of the Metabolic Effects of Food Product WBF-0011 in Type 2 Diabetes
This 12 week placebo-controlled study evaluates the safety and impact of 2 different strengths of the medical food formulation WBF-0011.
- Trial name
- NCT04047537
- Testing
- Medical Food Formulation 1, Medical Food Formulation 2
- Where
- Ireland
- Volunteers
- 41 people
- Sponsor
- Pendulum Therapeutics
HIV Infections, HIV Wasting Syndrome
Growth Hormone in the Treatment of HIV-Associated Wasting
The purpose of this study is to compare physical function and lean body mass in patients getting different doses of somatropin compared to patients not getting the drug.
- Trial name
- NCT00489528
- Testing
- Somatropin; Recombinant human growth hormone (r hGH)
- Sponsor
- EMD Serono
Obesity
Study To Determine The Effects And Safety Of A Weight Loss Compound On Overweight, Otherwise Healthy, Volunteers
The purpose of this study is to determine whether CP-866,087 is effective in the weight loss of overweight patients.
- Trial name
- NCT00479492
- Testing
- CP-866,087
- Where
- 4 sites in United States
- Volunteers
- 94 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.